Aptus Capital Advisors LLC Has $633,000 Stock Position in Intellia Therapeutics, Inc. $NTLA

Key Points

• Aptus Capital Advisors LLC reduced its stake in Intellia Therapeutics by 36%, selling 50,196 shares, and now holds approximately 0.09% of the company, valued at $633,000.
• Institutional investors own 88.77% of Intellia Therapeutics, with significant increases in holdings from firms like Voloridge Investment Management and Two Sigma Advisers.
• Intellia Therapeutics reported a revenue of $14.25 million for the recent quarter, surpassing analyst expectations, while its earnings per share improved to $(0.99), beating the consensus estimate.

Aptus Capital Advisors LLC trimmed its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 36.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 89,082 shares of the company's stock after selling 50,196 shares during the quarter. Aptus Capital Advisors LLC owned about 0.09% of Intellia Therapeutics worth $633,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new stake in shares of Intellia Therapeutics during the 4th quarter worth about $25,000. Sterling Capital Management LLC grew its stake in shares of Intellia Therapeutics by 866.2% in the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock worth $37,000 after purchasing an additional 2,867 shares during the last quarter. Harbour Investments Inc. grew its stake in shares of Intellia Therapeutics by 76.7% in the 1st quarter. Harbour Investments Inc. now owns 5,214 shares of the company's stock worth $37,000 after purchasing an additional 2,264 shares during the last quarter. Virtus ETF Advisers LLC grew its stake in shares of Intellia Therapeutics by 47.7% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,242 shares of the company's stock worth $61,000 after purchasing an additional 1,692 shares during the last quarter. Finally, 49 Wealth Management LLC acquired a new position in shares of Intellia Therapeutics in the 1st quarter worth approximately $74,000. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Stock Up 0.5%

NTLA stock traded up $0.06 during trading hours on Wednesday, hitting $11.42. The company's stock had a trading volume of 1,009,117 shares, compared to its average volume of 4,086,003. The company has a market capitalization of $1.23 billion, a PE ratio of -2.44 and a beta of 2.31. Intellia Therapeutics, Inc. has a 12 month low of $5.90 and a 12 month high of $23.76. The stock has a 50 day moving average price of $11.16 and a two-hundred day moving average price of $9.54.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.99) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.04. The company had revenue of $14.25 million during the quarter, compared to the consensus estimate of $12.26 million. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 57.48%. The company's revenue for the quarter was up 104.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.52) earnings per share. Sell-side analysts expect that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, Director William J. Chase acquired 100,000 shares of the company's stock in a transaction dated Wednesday, August 20th. The shares were acquired at an average cost of $10.03 per share, for a total transaction of $1,003,000.00. Following the completion of the purchase, the director owned 134,693 shares of the company's stock, valued at approximately $1,350,970.79. This trade represents a 288.24% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Edward J. Dulac III sold 7,462 shares of the stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total transaction of $104,617.24. Following the completion of the sale, the executive vice president directly owned 106,062 shares of the company's stock, valued at approximately $1,486,989.24. This trade represents a 6.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 12,534 shares of company stock valued at $153,837 over the last three months. Insiders own 3.10% of the company's stock.

Analysts Set New Price Targets

NTLA has been the subject of several research reports. Wedbush reissued a "neutral" rating and set a $7.00 price objective on shares of Intellia Therapeutics in a research note on Monday, June 16th. Citigroup reduced their price objective on Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. HC Wainwright dropped their target price on shares of Intellia Therapeutics from $30.00 to $25.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Royal Bank Of Canada dropped their target price on shares of Intellia Therapeutics from $25.00 to $21.00 and set an "outperform" rating on the stock in a research report on Friday, August 8th. Finally, Canaccord Genuity Group dropped their target price on shares of Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating on the stock in a research report on Tuesday, June 3rd. Twelve research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Intellia Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $29.05.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.